A global Phase III trial of 605 patients across the US and Europe has demonstrated therapeutic equivalence between Stelara (ustekinumab) and Dong-A ST’s biosimilar candidate DMB-3115.
The DMB-3115 global phase III began in the US in 2021 followed by eight European countries – including Poland, Estonia and